Bank of New York Mellon’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Bank of New York Mellon’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-44,720	Closed	-$5.88M	–	4402
2020 Q4	$5.88M	Sell	44,720 -2,052	-4%	-$181K	﹤0.01%	2284
2020 Q3	$2.36M	Buy	46,772 +1,986	+4%	+$89.3K	﹤0.01%	2572
2020 Q2	$2.13M	Sell	44,786 -11,792	-21%	-$548K	﹤0.01%	2641
2020 Q1	$2.77M	Buy	56,578 +1,383	+3%	+$70.5K	﹤0.01%	2373
2019 Q4	$3.17M	Buy	55,195 +11,957	+28%	+$592K	﹤0.01%	2575
2019 Q3	$1.55M	Sell	43,238 -21,629	-33%	-$845K	﹤0.01%	2893
2019 Q2	$2.02M	Buy	64,867 +18,933	+41%	+$513K	﹤0.01%	2791
2019 Q1	$1.08M	Buy	45,934 +18,253	+66%	+$293K	﹤0.01%	3121
2018 Q4	$381K	Buy	27,681 +13,991	+102%	+$177K	﹤0.01%	3613
2018 Q3	$137K	Buy	+13,690	New	+$225K	﹤0.01%	3993

Bank of New York Mellon's EIDX Position: Q1 2021 in Review

Bank of New York Mellon sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 44,720 shares — an estimated $5.88M sold.

Bank of New York Mellon first reported a position in EIDX in Q3 2018 and held it in 10 quarters. The position peaked at $5.88M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

Bank of New York Mellon reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Bank of New York Mellon sold 44,720 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $5.88M.
Bank of New York Mellon first reported a position in Eidos Therapeutics, Inc. Common Stock in Q3 2018 and held it in 10 quarters.
Bank of New York Mellon's Eidos Therapeutics, Inc. Common Stock position peaked at $5.88M in Q4 2020.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Bank of New York Mellon's 13F filing for Q1 2021, filed 13 May 2021.